Decoy Therapeutics Inc. (DCOY) stock
DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.95+0.05 (+5.37%)
Close on Nov 17, 2026Market cap $622.03KP/E –Yield –
Decoy Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Decoy Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.23M, up 342.1% year over year. For fiscal 2025 it was $368.17K, down 52.2% from the year before. Over ten years it grew -29.8% a year on average. The highest annual figure on record is $20.38M in fiscal 2016.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $368.17K | -52.2% |
| FY2024 | Dec 31, 2024 | $770.03K | -89.3% |
| FY2023 | Dec 31, 2023 | $7.17M | -54.7% |
| FY2022 | Dec 31, 2022 | $15.84M | +85.3% |
| FY2021 | Dec 31, 2021 | $8.55M | +23.6% |
| FY2020 | Dec 31, 2020 | $6.91M | +72.0% |
| FY2019 | Dec 31, 2019 | $4.02M | +212.1% |
| FY2018 | Dec 31, 2018 | $1.29M | -92.4% |
| FY2017 | Dec 31, 2017 | $16.99M | -16.6% |
| FY2016 | Dec 31, 2016 | $20.38M | +59.8% |
| FY2015 | Dec 31, 2015 | $12.75M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.30M | +1020.7% |
| Q1 FY2026 | Mar 31, 2026 | $749.81K | +892.7% |
| Q4 FY2025 | Dec 31, 2025 | $114.43K | -34.7% |
| Q3 FY2025 | Sep 30, 2025 | $61.83K | -54.9% |
| Q2 FY2025 | Jun 30, 2025 | $116.38K | -45.7% |
| Q1 FY2025 | Mar 31, 2025 | $75.53K | -68.9% |
| Q4 FY2024 | Dec 31, 2024 | $175.34K | +192.5% |
| Q3 FY2024 | Sep 30, 2024 | $137.23K | -86.8% |
| Q2 FY2024 | Jun 30, 2024 | $214.45K | -90.9% |
| Q1 FY2024 | Mar 31, 2024 | $243.00K | -93.5% |
| Q4 FY2023 | Dec 31, 2023 | $59.95K | -98.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.04M | -72.7% |
| Q2 FY2023 | Jun 30, 2023 | $2.35M | -19.5% |
| Q1 FY2023 | Mar 31, 2023 | $3.73M | -16.1% |
| Q4 FY2022 | Dec 31, 2022 | $4.69M | +73.8% |
| Q3 FY2022 | Sep 30, 2022 | $3.79M | +88.0% |
| Q2 FY2022 | Jun 30, 2022 | $2.92M | +39.4% |
| Q1 FY2022 | Mar 31, 2022 | $4.44M | +155.0% |
| Q4 FY2021 | Dec 31, 2021 | $2.70M | +33.2% |
| Q3 FY2021 | Sep 30, 2021 | $2.02M | +11.8% |
| Q2 FY2021 | Jun 30, 2021 | $2.10M | +45.2% |
| Q1 FY2021 | Mar 31, 2021 | $1.74M | +5.9% |
| Q4 FY2020 | Dec 31, 2020 | $2.02M | +51.2% |
| Q3 FY2020 | Sep 30, 2020 | $1.80M | +58.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.44M | +71.8% |
| Q1 FY2020 | Mar 31, 2020 | $1.64M | +134.8% |
| Q4 FY2019 | Dec 31, 2019 | $1.34M | +612.6% |
| Q3 FY2019 | Sep 30, 2019 | $1.14M | +222.6% |
| Q2 FY2019 | Jun 30, 2019 | $840.14K | -86.4% |
| Q1 FY2019 | Mar 31, 2019 | $699.93K | -85.0% |
| Q4 FY2018 | Dec 31, 2018 | $187.76K | -95.6% |
| Q3 FY2018 | Sep 30, 2018 | $353.61K | -92.5% |
| Q2 FY2018 | Jun 30, 2018 | $6.17M | +51.5% |
| Q1 FY2018 | Mar 31, 2018 | $4.68M | +19.5% |
| Q4 FY2017 | Dec 31, 2017 | $4.26M | +0.7% |
| Q3 FY2017 | Sep 30, 2017 | $4.74M | -16.3% |
| Q2 FY2017 | Jun 30, 2017 | $4.08M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.91M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.23M | – |
| Q3 FY2016 | Sep 30, 2016 | $5.67M | – |
See a number that looks wrong?